The Effects of Excipients on Freeze-dried Monoclonal Antibody Formulation Degradation and Sub-Visible Particle Formation during Shaking
Purposes We previously reported an unexpected phenomenon that shaking stress could cause more protein degradation in freeze-dried monoclonal antibody (mAb) formulations than liquid ones (J Pharm Sci, 2022, 2134). The main purposes of the present study were to investigate the effects of shaking stress on protein degradation and sub-visible particle (SbVP) formation in freeze-dried mAb formulations, and to analyze the factors influencing protein degradation during production and transportation. Methods The aggregation behavior of mAb-X formulations during production and transportation was simulated by shaking at a rate of 300 rpm at 25°C for 24 h. The contents of particles and monomers were analyzed by micro-flow imaging, dynamic light scattering, size exclusion chromatography, and ultraviolet − visible (UV–Vis) spectroscopy to compare the protective effects of excipients on the aggregation of mAb-X. Results Shaking stress could cause protein degradation in freeze-dried mAb-X formulations, while surfactant, appropriate pH, polyol mannitol, and high protein concentration could impact SbVP generation. Water content had little effect on freeze-dried protein degradation during shaking, as far as the water content was controlled in the acceptable range as recommended by mainstream pharmacopoeias (i.e., less than 3%). Conclusions Shaking stress can reduce the physical stability of freeze-dried mAb formulations, and the addition of surfactants, polyol mannitol, and a high protein concentration have protective effects against the degradation of model mAb formulations induced by shaking stress. The experimental results provide new insight for the development of freeze-dried mAb formulations..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Pharmaceutical research - 41(2024), 2 vom: 30. Jan., Seite 321-334 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jin, Meng-Jia [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Aggregation |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11095-024-03657-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054834937 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054834937 | ||
| 003 | DE-627 | ||
| 005 | 20240221064659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240221s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11095-024-03657-7 |2 doi | |
| 035 | |a (DE-627)SPR054834937 | ||
| 035 | |a (SPR)s11095-024-03657-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jin, Meng-Jia |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Effects of Excipients on Freeze-dried Monoclonal Antibody Formulation Degradation and Sub-Visible Particle Formation during Shaking |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purposes We previously reported an unexpected phenomenon that shaking stress could cause more protein degradation in freeze-dried monoclonal antibody (mAb) formulations than liquid ones (J Pharm Sci, 2022, 2134). The main purposes of the present study were to investigate the effects of shaking stress on protein degradation and sub-visible particle (SbVP) formation in freeze-dried mAb formulations, and to analyze the factors influencing protein degradation during production and transportation. Methods The aggregation behavior of mAb-X formulations during production and transportation was simulated by shaking at a rate of 300 rpm at 25°C for 24 h. The contents of particles and monomers were analyzed by micro-flow imaging, dynamic light scattering, size exclusion chromatography, and ultraviolet − visible (UV–Vis) spectroscopy to compare the protective effects of excipients on the aggregation of mAb-X. Results Shaking stress could cause protein degradation in freeze-dried mAb-X formulations, while surfactant, appropriate pH, polyol mannitol, and high protein concentration could impact SbVP generation. Water content had little effect on freeze-dried protein degradation during shaking, as far as the water content was controlled in the acceptable range as recommended by mainstream pharmacopoeias (i.e., less than 3%). Conclusions Shaking stress can reduce the physical stability of freeze-dried mAb formulations, and the addition of surfactants, polyol mannitol, and a high protein concentration have protective effects against the degradation of model mAb formulations induced by shaking stress. The experimental results provide new insight for the development of freeze-dried mAb formulations. | ||
| 650 | 4 | |a aggregation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a freeze-dried/drying |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a monoclonal antibody |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a shaking stress |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a sub-visible particle |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ge, Xin-Zhe |4 aut | |
| 700 | 1 | |a Huang, Qiong |4 aut | |
| 700 | 1 | |a Liu, Jia-Wei |4 aut | |
| 700 | 1 | |a Ingle, Rahul G. |4 aut | |
| 700 | 1 | |a Gao, Dong |4 aut | |
| 700 | 1 | |a Fang, Wei-Jie |0 (orcid)0000-0003-3375-7360 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical research |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1984 |g 41(2024), 2 vom: 30. Jan., Seite 321-334 |w (DE-627)SPR016546105 |w (DE-600)2036232-8 |x 1573-904X |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:2 |g day:30 |g month:01 |g pages:321-334 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11095-024-03657-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 2 |b 30 |c 01 |h 321-334 | ||